Please begin budgeting with the new composite fringe benefit rates listed in the table below for all future proposal submissions. Note these new rates will be required in all proposals submitted on or after August 15, 2017.
The effective date for the new fringe benefits rates to be charged to all sponsored projects is July 1st, 2017.
The new rates have been updated on the Proposal Preparation section of the ORSP website: http://academicdepartments.musc.edu/research/orsp/proposal_preparation/.
Cayuse424 has also been updated with these rates to be the default budget rates. Any pending proposals in Cayuse424 will need to be updated to the new rates. To accomplish this please re-autofill each investigator on the proposal using the “Manage Key Persons” button on the budget page. When the salary is updated, the system will capture the new fringe rate. Please direct any questions about this to your assigned Grants Administrator in ORSP.
Employee Benefits Category
Fringe Benefits Rate
Applicable Employment Types
Temp Faculty/Temp non-Faculty
Research Grant Employees- No Benefits
NIH Notice Number: NOT-OD-17-072 establishes the FY 2017 Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels.
From the Notice:
This revised Notice supersedes NOT-OD-16-062, and establishes stipend levels for fiscal year (FY) 2017 Kirschstein-NRSA awards for undergraduate and predoctoral trainees and fellows, as shown in the table below. The Training Related Expenses and Institutional Allowances for predoctoral trainees and fellows and the Tuition and Fees for all educational levels remain unchanged.
The budgetary categories described in this Notice apply only to Kirschstein-NRSA awards made with FY 2017 funds. All FY 2017 awards previously issued using FY 2016 stipend levels (NOT-OD-16-062) will be revised to adjust stipends to the FY 2017 level.
Appointments to institutional training grants that have already been awarded in FY 2017 must be amended to reflect the FY 2017 stipend levels once the training grant award has been adjusted by the NIH. Amended appointments must be submitted through xTrain in the eRA Commons. Retroactive adjustments or supplementation of stipends or other budgetary categories with Kirschstein-NRSA funds for an award made prior to October 1, 2016 are not permitted.
Note: The FY 2017 stipend and other budgetary levels for postdoctoral trainees and fellows was issued on December 15, 2016: NOT-OD-17-003
Stipends for FY 2017
Effective with all Kirschstein-NRSA awards made on or after October 1, 2017, the following annual stipend levels apply to all individuals receiving support through institutional research training grants or individual fellowships, including the Maximizing Access to Research Career (MARC) and Building Infrastructure Leading to Diversity (BUILD) programs.
Undergraduates in the MARC and BUILD Programs: For institutional training grants (T34, TL4), two stipend levels may be used for undergraduate candidates: Freshmen/Sophomores and Juniors/Seniors.
Stipend for FY 2017
Predoctoral Trainees and Fellows: For institutional training grants (T32, T35, T90, TL1) and individual fellowships (F30, F31, F99), one stipend level is used for all predoctoral candidates, regardless of the level of experience.
Years of Experience
Tuition and Fees, Training Related Expenses, and Institutional Allowance for Kirschstein-NRSA Recipients
The NIH will provide funds for Tuition and Fees, Training Related Expenses, and Institutional Allowance as detailed below.
A. Tuition and Fees
Undergraduate and Predoctoral Trainees and Fellows: For institutional training grants (T32, T34, T35, T90, TL1, TL4) and individual fellowships (F30, F31, F99), an amount per predoctoral trainee equal to 60% of the level requested by the applicant institution, up to $16,000 per year, will be provided. If the trainee or fellow is enrolled in a program that supports formally combined, dual-degree training (e.g., MD/PhD, DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), the amount provided per trainee or fellow will be 60% of the level requested, up to $21,000 per year.
B. Training Related Expenses on Institutional Training Grants
For institutional training grants (T32, T35, T90, TL1), these expenses (including health insurance costs) for predoctoral trainees will be paid at the amounts shown below for all competing and non-competing awards made with FY 2017 funds.
C. Institutional Allowance for Individual Fellows
This allowance for predoctoral fellows will be paid at the amounts shown below for all competing and non-competing awards made with FY 2017 funds.
Institutional Allowance for individual fellows (F30, F31, F99) sponsored by non-Federal Public, Private, and Non-Profit Institutions (Domestic & Foreign, including health insurance):
Institutional Allowance for individual fellows (F30, F31, F99) sponsored by Federal and For-Profit Institutions (including health insurance):
Current stipend levels are to be used in the preparation of future competing and non-competing NRSA institutional training grant and individual fellowship applications. They will be administratively applied to all applications currently in the review process.
NRSA support is limited to 5 years for predoctoral trainees (6 years for dual-degree training, e.g., MD/PhD, DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD).
It should be noted that the maximum amount that NIH will award to support the compensation package for a graduate student research assistant remains at the zero level postdoctoral stipend, as described in NOT-OD-02-017.
Frequently Asked Questions Related to NRSA Tuition, Fees, and Health Insurance Policies: http://grants.nih.gov/training/nrsa_tuition_q&a.htm.
This message serves as a reminder for everyone at MUSC to adhere to the policy on Appendix Materials in funding applications submitted to the National Institutes of Health (NIH), the Agency for Healthcare Research and Quality (AHRQ), or the National Institute for Occupational Safety and Health (NIOSH).
These federal agencies will administratively withdraw applications that include any disallowed materials in the Appendices. Such an oversight will prohibit the application from getting peer reviewed and scored.
This information has been added to the ORSP web page for quick reference (http://academicdepartments.musc.edu/research/orsp/policies_procedures/appendix_materials_NIH_AHRQ_NIOSH).
NOTE: the NIH FAQ link (https://grants.nih.gov/grants/policy/appendix_policy.htm) has been included to help clarify what is or is not allowed to be included in the Appendix Materials.
Notice NOT-OD-16-129 alerted the scientific research community of the elimination of most appendix materials for applications submitted to NIH, AHRQ or NIOSH for due dates on or after January 25, 2017.
The NIH, AHRQ, and NIOSH strive to ensure fairness in peer review for all grant applicants by specifying the types and amount of application material that are accepted for peer review. At the same time, these agencies appreciate both the need for applications to provide sufficient information to allow for an informed, expert review process and the importance of limiting the burden on peer reviewers.
Elimination of most appendix materials is intended to rectify inequities in the peer review process that can arise from submission of inappropriate or excessive appendix materials by some applicants and consideration of appendix materials in peer review by some, but not all reviewers.
Appendix materials in peer review
All information submitted with an application except the cover letter, assignment request form and appendix information are assembled into a single application image for funding consideration. The different sections within the application image are specified in the application instructions and correspond to the standard review criteria.
Allowable appendix materials
Beginning with applications submitted to the NIH, AHRQ, or NIOSH for due dates on or after January 25, 2017, the only allowable appendix materials are:
For applications proposing clinical trials (unless the FOA provides other instructions for these materials):
For all applications:
Consequences for submitting disallowed appendix materials
Applications submitted for due dates on or after January 25, 2017 will be withdrawn and not reviewed if they are submitted with appendix materials that are not specifically listed in this Notice or the FOA as allowed or required.
FAQs on the NIH/AHRQ/NIOSH Appendix Policy
Since the memo of understanding was signed in October 2016 to establish a new Office of Clinical Research, much of the activity has involved setting up MUSC’s newest Research Administration Office. Most of the staff have been hired and space secured in Suite 170 in the Roper Medical Office Building, just down the hall from the SCTR offices. New workflow processes and training are being developed, as well as tools and metrics, to guide study teams in understanding what research billing compliance entails. Clinical research billing compliance in this context is often referred to as prospective reimbursement analysis.
The purpose of the Office of Clinical Research is outlined below, but to better understand how the OCR fits into the MUSC Research community, this organization chart illustrates how we are positioned.
Important to note, is that the OCR is a collaboration between MUSC Administration, College of Medicine, and MUSC Health.
Effective May 1, all new clinical research studies must have a clinical billing compliance review called a Prospective Reimbursement Analysis (PRA). The OCR has been busy providing information for faculty members, and meeting and providing more detailed training to study team about the new PRA workflow process. The OCR PRA Team is seeking information from departments and the research community to improve the OCR and research processes.
The goal of the billing compliance review process is to facilitate the research study activation process as well as to ensure compliance, so please submit studies early in the study activation process. The OCR PRA Team will work alongside the study team to complete the PRA in parallel with the study team completing the budget. The PRA will provide valuable information to support budget development and contract negotiation. Eventually, the prospective reimbursement process (PRA) should improve the process and reduce the time of setting up a clinical research study.
We encourage the MUSC Research Community to visit the OCR internal website at: http://horseshoe.musc.edu/research/ocr. Browse the pages for Training and Resources, Announcements and updates both from the OCR and the Epic Research Team. Our external-facing website is primarily for industry sponsors.
The horseshoe sites are most easily accessed if you are on campus. If off campus, you may have use a VPN to log in. In addition, you can contact the OCR office at 843-792-7900 or at email@example.com.
Notice NOT-OD-17-062 announced a transition from the current NIH grant application forms (“FORMS-D”) to the next iteration of forms (“FORMS-E”) for due dates on or after January 25, 2018.
Highlights of the new FORMS-E will include:
Application guides for FORMS-E application packages will be posted to the How to Apply - Application Guide page no later than October 25, 2017.
All NIH "parent" announcements that use standard due dates will be expired and reissued with new FOA numbers, FORMS-E application packages and instructions. The FORMS-E parent announcements will be posted no later than 60 days before their standard due date. For a transition period, both FORMS-D and FORMS-E parent announcements will be active. Applicants must choose the announcement with the appropriate application package for their due date (see table below).
All active FOAs with due dates both before and after January 25, 2018 will be updated to add FORMS-E application packages between October 25, 2017 and November 25, 2017. For a transition period, both FORMS-D and FORMS-E application packages will be active. Applicants must choose the appropriate application package for their due date when presented with both FORMS-D and FORMS-E application packages on the same FOA (see table below).
If your due date is…
You must use…
On or before January 24, 2018, including:
FORMS-D application package
On or after January 25, 2018, including:
FORMS-E application package
Additional guide notices for individual FOAs with unique due date considerations will be issued as needed and referenced in the Related Notices section of each FOA.
Form Update Timing for Administrative Supplement, Successor-in-Interest (Type 6) and Change of Institution (Type 7) Parent Announcements
Parent announcements for administrative supplements and post award administrative actions (successor-in-interest and change of institution applications) do not have set due dates and, consequently, will follow a different timeline than other parent announcements.
The FOAs in the table below will be reissued with new FOA numbers, FORMS-E application packages and instructions on January 25, 2018. Applications started on or after January 25, 2018 must use the new FOAs and FORMS-E application packages.
These FOAs will expire on February 25, 2018 giving applicants one month to complete their initiated FORMS-D applications.
Change of Grantee Organization (Type 7 Parent)
Successor-in-Interest (Type 6 Parent)
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Admin Supp)
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)
Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp)
Applications Proposing Clinical Trials
As previously announced, all applications involving clinical trials must be submitted to FOAs specifically designed for clinical trials beginning with due dates on or after January 25, 2018 (NOT-OD-16-147, NOT-OD-17-043).
NIH will take the following steps to accommodate this new policy:
A new notice from the NIH (Reporting Preprints and Other Interim Research Products, NOT-OD-17-050) indicates that interim research products, including preprints, can soon be cited where other research products are cited. This includes the NIH Biosketch and Section C of the Research Performance Progress Report (RPPR), among others. The change is effective for all applications submitted for the May 25, 2017 due date and beyond, and for RPPRs submitted on or after May 25, 2017.
What are Interim Research Products?
NIH defines interim research products as complete, public research products that are not final. A common form is the preprint, which is a complete and public draft of a scientific document. Preprints are typically manuscripts written in the style of a peer-reviewed journal article that have not been subject to peer review. Scientists issue preprints to speed dissemination, establish priority, obtain feedback, and offset publication bias.
Citing Interim Research Products
When citing an interim research product, applicants and awardees must include the Digital Object Identifier and the Object type (e.g. preprint, protocol) in the citation. They should also list any information about the document version (e.g. most recent date modified), and if relevant, the date the product was cited.
Bar DZ, Atkatsh K, Tavarez U, Erdos MR, Gruenbaum Y, Collins FS. Biotinylation by antibody recognition- A novel method for proximity labeling. BioRxiv 069187 [Preprint]. August 11, 2016 [cited 2017 Jan 12]. Available from: https://doi.org/10.1101/069187.
For more information, see: NIH NOT-OD-17-050: Reporting Preprints and Other Interim Research Products.
In October 2016, the NIH requested information on the use of interim research products and standards for reporting them (Request for information (RFI): Including Preprints and Interim Research Products in NIH Applications and Reports, NOT-OD-17-006). The NIH received 351 responses and nearly all respondents supported increasing the use of interim research products in NIH award processes. Specific benefits of interim research products include speeding dissemination of results, enhancing the rigor of the research and avoiding publication bias. For more information about the responses, see the Background and Public Comments section of: NIH NOT-OD-17-050: Reporting Preprints and Other Interim Research Products.
The Final Notice of Research Terms and Conditions (RTC) To Address and Implement the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards Issued by the U.S. Office of Management and Budget (OMB) was published in the March 14 Federal Register.
These RTCs are the successor to the terms developed with the Federal Demonstration Partnership, and they have been written to comply with the requirements set out in the Uniform Guidance (2 CFR 200). Agencies are planning to implement the RTCs at different dates in 2017.
Agencies participating, with implementation dates, are:
Note that the Department of Defense is not included; but will implement award terms in compliance with 2 CFR 200.
While the Uniform Guidance outlines provisions that are specific to research, these terms and conditions:
Incorporate the entire Uniform Guidance by reference, clarifying or supplementing select provisions where appropriate and consistent with government-wide research policy.
Incorporate the latest version of the Frequently Asked Questions for the Office of Management and Budget's Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards at 2 CFR 200.
Apply to an award when included as part of the award or when incorporated in the award by reference. Use of the RTCs is envisioned as a streamlined approach that supports the implementation of the Uniform Guidance by providing clarification, supplementary guidance, and, where appropriate, selected options, while meeting the spirit and intent of a uniform implementation.
In addition to the RTCs, three companion resources will be developed: Appendix A, Prior Approval Matrix; Appendix B, Subaward Requirements Matrix; and Appendix C, National Policy Requirements Matrix.
Per NIH notice NOT-OD-17-049, the new NIH salary cap is $187,000 effective January 8, 2017.
Salaries up to this new $187,000 level are allowed to be charged starting January 8, 2017, to NIH funded grants provided the necessary funds are available.
NOTE: No additional funds will be provided by NIH.
Once the Department of Health and Human Services Appropriation for FY 2017 is enacted, NIH will publish the annual Notice of legislative mandates to provide information on any statutory provisions that limit the use of NIH grant funds in FY 2017. Additional guidance on the salary cap will also be provided at that time.
For those planning to make payroll adjustments due to this salary cap increase, we encourage using February 1st, 2017, as the start date for any changes. Start dates other than the first day of the month may lead to errors due to the manual calculations required.
When preparing all future NIH grant proposals, please use the new salary cap maximum. Both the ORSP Proposal Preparation page and Cayuse data are being updated to reflect the new NIH Salary Cap level.
NIH Shared Instrumentation Grant (S10) Applications
Additional Information link: http://academicdepartments.musc.edu/research/ord/fundingops/secure/SIG_SIFAR.pdf
Then you should know that MUSC has adopted a new campus policy for the review and approval of human pluripotent stem cell research. The “MUSC Research Using Human Stem Cells Policy” will take effect on July 1, 2017. In order to be compliant, MUSC leadership has charged a new oversight body, the Stem Cell Research Oversight (SCRO) committee, with oversight responsibilities for all research projects that fall under this policy.
Applicability and Scope of Oversight of the SCRO Policy
The scope of the MUSC Research Using Human Stem Cells Policy is limited to a well-defined subset of life sciences research that involves the storage of human embryonic stem cells and the derivation or use of all types of human pluripotent stem cells at MUSC. The aim of this policy is to help ensure that such research is conducted with the highest ethical and scientific research standards, and in compliance with all applicable federal and state regulations, MUSC policies, and the requirements of extramural research sponsors. Non-compliance with this Policy may result in suspension, limitation, or termination of Federal research funding.
Principal Investigator Responsibilities
It is the responsibility of the Principal Investigator to identify research involving the derivation or use of human pluripotent stem cells and notify the SCRO for review.
SCRO Notification of Research with Human Stem Cells
The formal SCRO review starts with the PI submission of a SCRO registration form. Instructions for submitting this form are available on the SCRO website. The SCRO will review the application and determine whether or not the project indeed falls into the scope of human stem cell research oversight. All individuals involved in this scope of research will be required to complete the SCRO training module in the online CITI Human Stem Cell program.
Researchers with questions are encouraged to talk to the SCRO Program Manager (Dr. Yashmin Karten, 843-792-6521, firstname.lastname@example.org).
MUSC website on SCRO
MUSC Research Using Human Stem Cells Policy
National Academies of Sciences Guidelines
NIH Guidelines on Human Stem Cell Research
NIH Human Embryonic Stem Cell Registry
International Society for Stem Cell Research